IQUIX Drug Patent Profile

When do Iquix patents expire, and when can generic versions of Iquix launch?

Iquix is a drug marketed by Santen and is included in one NDA.

The generic ingredient in IQUIX is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Iquix

A generic version of IQUIX was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for IQUIX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	98
Patent Applications:	5,337
DailyMed Link:	IQUIX at DailyMed

US Patents and Regulatory Information for IQUIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santen	IQUIX	levofloxacin	SOLUTION/DROPS;OPHTHALMIC	021571-001	Mar 1, 2004		DISCN	Yes	No

Expired US Patents for IQUIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Santen	IQUIX	levofloxacin	SOLUTION/DROPS;OPHTHALMIC	021571-001	Mar 1, 2004	5,053,407

EU/EMA Drug Approvals for IQUIX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789 Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

International Patents for IQUIX

See the table below for patents covering IQUIX around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	175312
Norway	862426
Croatia	P950176	OPTICALLY ACTIVE BENZOXAZINE DERIVATIVES
Finland	884331
Yugoslavia	45512
Spain	556292
Bulgaria	60527

Supplementary Protection Certificates for IQUIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0206283	SPC/GB97/085	United Kingdom		PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606

IQUIX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Iquix (Levofloxacin Ophthalmic)

Introduction

Iquix, a topical fluoroquinolone antibiotic, was approved by the FDA on March 1, 2004, for the treatment of bacterial corneal ulcers. Here, we will delve into the market dynamics and financial trajectory of Iquix, although it is now discontinued.

Market Approval and Initial Impact

When Iquix was first approved, it filled a specific niche in the ophthalmic market by providing a treatment option for bacterial corneal ulcers. The approval marked a significant milestone for Santen, the company behind Iquix, as it expanded their portfolio in ophthalmic care[4].

Market Competition

The ophthalmic antibiotic market is competitive, with several other fluoroquinolones and antibiotics available. The level of competition can significantly impact the pricing and market share of a drug. For instance, studies have shown that drugs with fewer competitors tend to have higher prices, while those with multiple manufacturers see a decrease in pricing[1].

Financial Performance

Although specific financial data for Iquix is not readily available due to its discontinued status, we can infer some insights from general trends in the pharmaceutical industry. When a new drug is introduced, it often experiences a period of high revenue growth driven by its novelty and lack of generic competition.

Revenue Growth and Market Share

In the initial years following its approval, Iquix likely generated significant revenue for Santen. However, as with many prescription drugs, the revenue trajectory would have been influenced by factors such as competition from generics, other treatment options, and changes in market demand.

Generic Competition and Patent Expiry

The introduction of generic versions of levofloxacin ophthalmic would have significantly impacted Iquix's revenue. Generic drugs typically lead to a substantial decrease in the market share and revenue of the branded version, as generics are often priced lower and attract a larger customer base.

Discontinuation and Market Impact

Iquix was eventually discontinued, which could be due to various reasons such as declining market share, increased competition, or strategic decisions by the manufacturer. The discontinuation would have marked the end of Iquix's financial trajectory in the market.

Comparison with Other Pharmaceutical Trends

To put the financial trajectory of Iquix into perspective, consider the broader trends in the pharmaceutical industry. For example, biological products have seen a significant increase in spending despite a relatively stable number of prescriptions, indicating higher spending per prescription. In contrast, small molecule drugs like Iquix have seen more stable or even decreasing expenditures over time[1].

Industry Expert Insights

Industry experts often highlight the importance of innovation and competition in driving the financial performance of pharmaceutical companies. For instance, companies like UCB and Blueprint Medicines are focusing on launching new products and expanding their portfolios to drive growth and maintain a strong financial position[2][3].

Illustrative Statistics

• The total inflation-adjusted expenditures on prescription drugs grew from $522 billion in 2017 to $618 billion in 2022, an 18.4% increase. This growth was largely driven by biological products, which saw a 54.6% increase in expenditures during the same period[1].
• Companies like UCB have seen significant growth from newly launched products, such as EVENITY® and BIMZELX®, which more than doubled their net sales in recent years[3].

Examples from Similar Markets

The ophthalmic market, like other specialized drug markets, is subject to intense competition and regulatory scrutiny. For example, the launch of new treatments like RYSTIGGO® for generalized myasthenia gravis by UCB demonstrates how new products can drive revenue growth and market expansion[3].

Regulatory and Market Factors

Regulatory approvals and market dynamics play crucial roles in the financial trajectory of any drug. The FDA's acceptance and approval process, as well as post-marketing surveillance, can significantly impact a drug's market performance.

Key Takeaways

• Market Competition: The level of competition in the prescription drug market significantly affects pricing and revenue.
• Generic Competition: The introduction of generic versions can drastically reduce the revenue of branded drugs.
• Regulatory Factors: FDA approvals and post-marketing regulations are critical for a drug's market success.
• Innovation: Continuous innovation and the launch of new products are key drivers of growth in the pharmaceutical industry.

FAQs

Q: What was Iquix used for? A: Iquix was used for the treatment of bacterial corneal ulcers.

Q: When was Iquix approved by the FDA? A: Iquix was approved by the FDA on March 1, 2004.

Q: Why was Iquix discontinued? A: The exact reasons for the discontinuation of Iquix are not specified, but common reasons include declining market share, increased competition, or strategic decisions by the manufacturer.

Q: How does generic competition affect branded drugs? A: Generic competition typically leads to a significant decrease in the market share and revenue of branded drugs due to lower pricing.

Q: What are some key factors influencing the financial trajectory of pharmaceutical drugs? A: Key factors include market competition, generic competition, regulatory approvals, and continuous innovation.

Cited Sources

1. Competition in Prescription Drug Markets, 2017-2022 - ASPE Report
2. Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Blueprint Medicines
3. UCB on Growth Path for a Decade Plus - UCB Press Release
4. Iquix (levofloxacin ophthalmic) FDA Approval History - Drugs.com